西洛他唑和前列腺素E1对早期糖尿病肾病患者血清胱抑素C的影响

Effects of Cilostazol and Prostaglandin E1 on serum cystatin C in patients with early diabetic nephropathy

目的:探究早期糖尿病肾病患者临床使用西洛他唑、前列腺素E1药物治疗,临床血清胱抑素C水平变化。方法:以我院2014.9至2016.10期间住院部收治的80例早期糖尿病肾病患者为研究对象,完全随机将患者分为对比组(氯沙坦)、观察1组(用药西洛他唑)、观察2组(加用前列腺素E1)以及联合组(西洛他唑、前列腺素E1),每组20例,检测治疗前后患者血清胱抑素C、尿微量白蛋白等指标变化情况,对疾病治疗效果进行评估,统计治疗期间用药所致不良反应。结果:联合组疾病改善率为95.0%,明显高于观察1组、观察2组85.0%、80.0%(P<0.05);入院时指标组间比较差别无意义(P>0.05),用药后观察1、2组组间差别无统计学意义(P>0.05),联合组肾功能指标改善优于其他两组(P<0.05)。结论:临床对早期糖尿病肾病患者以西洛他唑、前列腺素E1联合治疗,患者肾功能恢复效果好、症状改善情况佳。

Objective：To investigate the clinical changes of serum cystatin C in patients with early diabetic nephropathy,who received clinical treatment with Cetostazol and Prostaglandin E1.Methods：Eighty patients with early diabetic nephropathy, who were hospitalized in the inpatient department between September 2014 and October 2016,were included in the study,and randomly divided into the control group （ Losartan） ,study group 1 （Cilostazol）,study group 2 （Prostaglandin E1） and the combined group （Cilostazol and Prostaglandin E1）,n=20 each. The changes of serum cystatin C and urinary albumin in patients before and after treatment were evaluated,and the effect of the treatment was evaluated. The adverse reactions caused by medication were statistically analyzed. Results：The improvement rate was 95.0% in the combined group,which was significantly higher than that in the study groups 1 and 2 （85.0%,80.0%,P〈0.05）. There was no significant difference in the indexes at the baseline between the two groups （ P〉0. 05 ） . There was no statistically significant difference between the study groups 1 and 2 after the treatment （ P〉0.05） . The improvement of renal function index in the combined group was better than that in the other two groups （P〈0.05）. Conclusion：The clinical treatment of early diabetic nephropathy with Cilostazol and Prostaglandin E1 show good recovery of renal function and improved symptoms in patients.